Published in Arthritis Rheum on June 01, 2010
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. Nat Immunol (2011) 1.46
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis (2011) 1.28
Progranulin: a promising therapeutic target for rheumatoid arthritis. FEBS Lett (2011) 1.20
Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep (2012) 1.17
Progranulin: a growth factor, a novel TNFR ligand and a drug target. Pharmacol Ther (2011) 1.16
TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol (2015) 1.10
The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand. Mol Cell Biol (2012) 0.88
Mast cell mediators in tolerance. Curr Opin Immunol (2010) 0.86
New discovery rarely runs smooth: an update on progranulin/TNFR interactions. Protein Cell (2015) 0.84
Mechanisms of tissue damage in arthritis. Semin Immunopathol (2014) 0.83
Altered bone biology in psoriatic arthritis. Curr Rheumatol Rep (2012) 0.80
Dampened ERK signaling in hematopoietic progenitor cells in rheumatoid arthritis. Clin Immunol (2012) 0.80
Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis. Arthritis Res Ther (2015) 0.80
Administration of progranulin (PGRN) triggers ER stress and impairs insulin sensitivity via PERK-eIF2α-dependent manner. Cell Cycle (2015) 0.78
Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J Biol Chem (2014) 0.78
Inhibiting TNF-α signaling does not attenuate induction of endotoxin tolerance. J Inflamm Res (2014) 0.75
[Biologics. Magic bullets - magic effects - magic costs? New therapeutics and their effects]. Ophthalmologe (2011) 0.75
Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature (2002) 45.19
Proteome survey reveals modularity of the yeast cell machinery. Nature (2006) 20.77
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 12.16
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42
Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol (2007) 8.47
The minimum information required for reporting a molecular interaction experiment (MIMIx). Nat Biotechnol (2007) 8.24
An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol (2009) 7.93
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol (2004) 7.23
ELM server: A new resource for investigating short functional sites in modular eukaryotic proteins. Nucleic Acids Res (2003) 6.86
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Peroxisomes are signaling platforms for antiviral innate immunity. Cell (2010) 5.24
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature (2006) 5.19
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther (2005) 4.86
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods (2013) 4.34
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest (2012) 4.31
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol (2011) 4.18
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
A myristoyl/phosphotyrosine switch regulates c-Abl. Cell (2003) 3.48
An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat Methods (2006) 3.38
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis (2013) 3.25
Target profiling of small molecules by chemical proteomics. Nat Chem Biol (2009) 3.20
Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol (2004) 3.10
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum (2007) 3.02
Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med (2008) 2.97
Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol (2002) 2.97
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis (2010) 2.91
Structure-based assembly of protein complexes in yeast. Science (2004) 2.89
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J Biol Chem (2001) 2.76
Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum (2005) 2.76
Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol (2010) 2.70
Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis (2012) 2.66
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun (2012) 2.65
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59
Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum (2010) 2.54
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell (2008) 2.46
Rediscovering the sweet spot in drug discovery. Drug Discov Today (2003) 2.45
Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab (2008) 2.44
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest (2009) 2.42
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.40
Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis (2013) 2.40
NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol (2009) 2.39
Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol (2015) 2.39
The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab (2012) 2.36
Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol (2008) 2.32
Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell (2006) 2.28
HuR as a negative posttranscriptional modulator in inflammation. Mol Cell (2005) 2.27
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.24
Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. Arthritis Rheum (2013) 2.22
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol (2005) 2.19
Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 2.14
RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell (2004) 2.13
Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol (2003) 2.12
Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum (2007) 2.12
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell (2011) 2.11
Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum (2012) 2.10
FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses. Immunity (2006) 2.10
High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med (2006) 2.09
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta Diabetol (2014) 2.07
Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. Arthritis Rheumatol (2014) 2.06
Mass spectrometry-based functional proteomics: from molecular machines to protein networks. Nat Methods (2007) 2.06
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2012) 2.06
12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity (2012) 2.06
Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med (2011) 2.05
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis (2013) 2.05
Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum (2009) 2.04
The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis (2012) 2.03
c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol Cell Biol (2002) 1.98
Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med (2008) 1.98
Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med (2013) 1.98
Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis (2011) 1.97
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A (2011) 1.95